This Article Full Text (PDF) All Versions of this Article: 0269881108089596v1 23/2/123    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Martinotti, G Articles by Janiri, L Search for Related Content PubMed PubMed Citation Articles by Martinotti, G Articles by Janiri, L Social Bookmarking                         What's this?

Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. Naltrexone

Department of Psychiatry, Catholic University Medical School, Rome, Italy giovanni.martinotti{at}libero.it

M Di Nicola

Department of Psychiatry, Catholic University Medical School, Rome, Italy

M Di Giannantonio

Department of Psychology, G. D’Annunzio University, Chieti, Italy

L Janiri

Department of Psychiatry, Catholic University Medical School, Rome, Italy

Abstract

Substantial evidence suggests that both partial dopamine agents and mixed 5-HT1A/2A receptor drugs independently show significant efficacy in reducing alcohol use in both animals and humans. Aripiprazole, which acts as a dopamine/5-HT system stabilizer, approaches the optimal characteristics sought in medication to be considered for testing in the treatment of alcohol dependence. In this randomised, double-blind, confrontation trial with naltrexone, we aimed to investigate the efficacy of aripiprazole on alcohol-drinking indices. Craving and psychiatric symptom improvements were the secondary end points. Seventy-five alcohol dependent subjects were detoxified and were subsequently randomised into two groups, receiving 50 mg of naltrexone and 5–15 mg of aripiprazole, respectively. Craving (Visual Analogue Scale; Obsessive and Compulsive Drinking Scale) and withdrawal (Clinical Institute Withdrawal Assessment) rating scales were applied; psychiatric symptoms were evaluated through the Symptom Check List 90–Revised. The number of subjects remained alcohol free for the entire study period (16 weeks) and the number of subjects relapsed were not significantly different in the two groups. The survival function showed that patients treated with aripiprazole remained abstinent from any alcohol amount for a longer time with respect to those treated with naltrexone. As for craving scores, patients treated with naltrexone showed a better outcome. Results from this study globally place aripiprazole at the same range of efficacy of naltrexone, one of the approved drugs used in alcohol relapse prevention. If it could be demonstrated in placebo-controlled trials that aripiprazole is efficacious in decreasing alcohol use, lessening craving, and attenuating psychopathological symptom severity, we will have gained a powerful agent for the treatment of alcohol-dependent subjects.

Key Words: alcohol dependence • craving • dopamine • dual diagnosis • partial agonists

This version was published on March 1, 2009

Journal of Psychopharmacology, Vol. 23, No. 2, 123-129 (2009)
DOI: 10.1177/0269881108089596


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?